

21 February 2023 BPC-A-46-2023\_rev2

# Draft agenda 46<sup>th</sup> meeting of the Biocidal Products Committee (BPC) 1-2 March 2023 Meeting is held virtually in Webex

## Starts on 1 March at 10:30, ends on 2 March at 18:00 The time is indicated in <u>Helsinki time</u>.

1. – Welcome and apologies

2. - Agreement of the agenda

BPC-A-46-2023

For agreement

3. – Declarations of potential conflicts of interest to agenda items

### 4. – Agreement of the minutes and review of actions from BPC-45

BPC-M-45-2022

For agreement

#### 5. – Administrative issues

5.1. Administrative issues

For information

#### 6. – Work programme for BPC

6.1. BPC Work Programmes for active substance approval, Union authorisation, ED assessment and outlook for BPC

BPC-46-2023-01; BPC-46-2023-02; BPC-46-2023-03; BPC-46-2023-04 For information

6.2. Update on active substance approval and Union authorisation *For information* 

6.3. Procedure for the submission, evaluation and dissemination of data generated after active substance approval

BPC-46-2023-05 For discussion

#### 7. – Applications for approval of active substances\*

7.1. Draft BPC opinion on Nitrogen generated from ambient air (inclusion in Annex I)

Previous discussion: WG-IV-2022

BPC-46-2023-06A, B, C *For adoption* 

**7.2.** Combined List of Endpoint for ozone generated from oxygen *Previous discussion: BPC-41 & BPC-44* 

BPC-46-2023-07 *For information* 

#### 8. – Union authorisation\*\*

8.1. Draft BPC opinion on an Union authorisation application for a biocidal product family containing mixture of 5-chloro-2-methyl-2H- isothiazol-3-one (EINECS 247-500-7) and 2-methyl-2H-isothiazol-3-one (EINECS 220-239-6) (Mixture of CMIT/MIT) for PT 6, 11, 12, 13

Previous discussion: WG-IV-2022

BPC-46-2023-08A, B, C, D, E, F, G *For adoption* 

8.2. Draft BPC opinion on an Union authorisation application for a biocidal product family containing peracetic acid for PT 2 Previous discussion: WG-IV-2022

> BPC-46-2023-09A, B, C, D, E *For adoption*

8.3. Harmonisation of the calculation of the PAA concentration from the product dilution

BPC-46-2023-10 *For discussion* 

<sup>\*</sup> For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft assessment report (AR) which may cover more than one PT (denoted by B) and a document containing open issues covering all the PTs to be discussed for that substance (denoted by C).

<sup>\*\*</sup> For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft Summary of Product Characteristics (SPC) (denoted by B), a draft product assessment report (PAR) (denoted by C) and a document containing open issues to be discussed for the biocidal product or biocidal product familiy (denoted by E).

#### 9. – Article 38 opinion requests

9.1. Draft BPC opinion on unresolved objections during a mutual recognition procedure for a PT 3 biocidal product intended for disinfection of livestock animals housings and equipment, and animal transportation vehicles

BPC-46-2023-11A, B, C, D *For adoption* 

9.2. Request for a BPC opinion on unresolved objections during a mutual recognition procedure for a PT 5 biocidal product family intended for disinfection of drinking water for animals

BPC-46-2023-12A, B For information

10. – Article 75(1)(g) opinion requests

10.1. Request for a BPC opinion on re-assessing the risk on the environment (soil compartment) posed by ADBAC/BKC from use in biocidal products of PT 2

BPC-46-2023-13 *For information* 

10.2. Request for a BPC opinion on evaluation of the availability and suitability of alternatives to RP 1:1 (PT 2, 6, 11, 13) and RP 3:2 (PT 2, 6, 11, 12, 13)

BPC-46-2023-14 For information

11. - Any other business

12. – Action points and conclusions



# Provisional time schedule for the 46<sup>th</sup> meeting of the Biocidal Products Committee (BPC)

#### Virtual meeting in WebEx

Please note that the time schedule indicated below is provisional and subject to possible change. The schedule is distributed to participants on a preliminary basis. If needed, follow-up discussions may take place on the following day for BPC opinions.

#### Wednesday 1 March: (starts at 10:30 EET/09:30 CET, ends at 18:00 EET/17:00 CET)

Items 1-5	Opening items and administrative issues
Item 6.1	BPC Work Programmes for active substance approval, Union authorisation, ED assessment and outlook for BPC
Item 7.1	Draft BPC opinion on Nitrogen generated from ambient air (inclusion in Annex I)
Item 7.2	Combined List of Endpoint for ozone generated from oxygen
Item 9.1	Draft BPC opinion on unresolved objections during a mutual recognition procedure for a PT 3 biocidal product intended for disinfection of livestock animals housings and equipment, and animal transportation vehicles
Item 9.2	Request for a BPC opinion on unresolved objections during a mutual recognition procedure for a PT 5 biocidal product family intended for disinfection of drinking water for animals
Item 10.1	Request for a BPC opinion on re-assessing the risk on the environment (soil compartment) posed by ADBAC/BKC from use in biocidal products of PT 2
Item 10.2	Request for a BPC opinion on evaluation of the availability and suitability of alternatives to RP 1:1 (PT 2, 6, 11, 13) and RP 3:2 (PT 2, 6, 11, 12, 13)

#### Thursday 2 March: (starts at 10:30 EET/09:30 CET, ends at 18:00 EET/17:00 CET)

Item 6.2	Update on active substance approval and Union authorisation
Item 6.3	Procedure for the submission, evaluation and dissemination of data generated after active substance approval
Item 8.1	Draft BPC opinion on an Union authorisation application for a biocidal product family containing mixture of 5-chloro-2-methyl-2H- isothiazol-3-one (EINECS 247-500-7) and 2-methyl-2H-isothiazol-3-one (EINECS 220-239-6) (Mixture of CMIT/MIT) for PT 6, 11, 12, 13
Item 8.2	Draft BPC opinion on an Union authorisation application for a biocidal product family containing peracetic acid for PT 2
Item 8.3	Harmonisation of the calculation of the PAA concentration from the product dilution
Item 11	Any other business
Item 12	Action points and conclusions

End of meeting

000